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Abstract Patients in the placebo arms of randomized controlled trials (RCT) often
experience positive changes from baseline. While multiple theories concerning such
‘‘placebo effects’’ exist, peculiarly, none has been informed by actual interviews
of patients undergoing placebo treatment. Here, we report on a qualitative study
(n = 27) embedded within a RCT (n = 262) in patients with irritable bowel syn-
drome. Besides identical placebo acupuncture treatment in the RCT, the qualitative
study patients also received an additional set of interviews at the beginning,
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DOI 10.1007/s11013-009-9141-7midpoint, and end of the trial. Interviews of the 12 qualitative subjects who under-
went and completed placebo treatment were transcribed. We found that patients (1)
were persistently concerned with whether they were receiving placebo or genuine
treatment; (2) almost never endorsed ‘‘expectation’’ of improvement but spoke of
‘‘hope’’ instead and frequently reported despair; (3) almost all reported improvement
ranging from dramatic psychosocial changes to unambiguous, progressive symptom
improvement to tentative impressions of beneﬁt; and (4) often worried whether their
improvement was due to normal ﬂuctuations or placebo effects. The placebo treat-
ment was a problematic perturbation that provided an opportunity to reconstruct the
experiences of the ﬂuctuations of their illness and how it disrupted their everyday
life. Immersion in this RCT was a co-mingling of enactment, embodiment and
interpretation involving ritual performance and evocative symbols, shifts in bodily
sensations, symptoms, mood, daily life behaviors, and social interactions, all
accompanied by self-scrutiny and re-appraisal. The placebo effect involved a
spectrum of factors and any single theory of placebo—e.g. expectancy, hope, con-
ditioning, anxiety reduction, report bias, symbolic work, narrative and
embodiment—provides an inadequate model to explain its salubrious beneﬁts.
Keywords Placebo effect  Placebo controls  Randomized controlled trials 
Placebo  Acupuncture  Irritable bowel syndrome  Patient–physician relationship 
Expectancy  Conditioning  Anxiety reduction  Report bias  Embodiment 
Ritual
Introduction
Biomedicine created the apparatus of the placebo-controlled randomized clinical
trial (RCT) so that highly variable human clinical conditions can be studied with the
mathematical precision of the laboratory experiment. Such trials provide the
evidence for claiming that biomedical therapies are scientiﬁc and actually provide
more than the effects of participation in a healing ritual (Kaptchuk 1998a).
Operationally, the RCT separates the effects of the ritual of treatment (conveniently
segregated in the placebo controls) from the presumptively objective effects of
pharmacological medications or physiologically active procedures (Kaptchuk
1998b; Kaptchuk et al. 2009). For biomedicine, the placebo effect demarcates
legitimate from illegitimate healing (Sullivan 1993; Kaptchuk 2003).
Yet patients frequently report relief in the placebo-control arms of RCTs, thereby
creating a conundrum for the centrality of pharmacological mechanisms in
biomedicine (Comaroff 1976). While some of the amelioration observed in placebo
groups is undoubtedly related to the natural course of an illness, spontaneous
remission and regression to the mean, recent sophisticated laboratory studies of
placebo treatment indicate the existence of a genuine short-term placebo effect
beyond natural history. These experiments have revealed both behavioral changes
and quantiﬁable objective changes in neurotransmitters, hormones, immune
regulators and regionally speciﬁc brain activity that could inﬂuence peripheral
disease processes through plausible physiological mechanisms (Benedetti et al.
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1232005; Kong et al. 2007; Benedetti 2008; Enck et al. 2008). How these laboratory
effects, often obtained on health normal volunteers, in artiﬁcial circumstances,
apply to various clinical conditions over longer periods of time remains unclear
(Kamper et al. 2008; Hro ´bjartson and Gotzsche 2001).
Within biomedicine (and also psychology), the two dominant conceptual models
for placebo effects are expectancy and classical conditioning. Expectancy posits that
the key factor involved in the placebo effect is cognitive, that is, what the patient
thinks or expects to happen as a result of treatment (Kirsch 1985, 2004). The
‘‘strength’’ of an expectation is usually regarded as measurable and stable, and the
basis for predicting deﬁnable outcomes. Discussions of what might mediate
expectancy to placebo treatment invoke notions of trust, beliefs, faith or the patient–
healer relationship (Kirsch 1997). That expectancies can lead to symptom
improvement and that these improvements have physiological correlates has been
supported by recent laboratory experiments that administer noxious stimuli (e.g.,
pain) and then provide strong expectancies plus placebo treatment and observe
symptom improvement (e.g., analgesia) along with measurable biochemical (e.g.,
endorphins, dopamine) and brain neuroanatomical correlates (e.g., rostral anterior
cingulated cortex, right anterior insula) (Zubieta et al. 2005; Kong et al. 2006; Scott
et al. 2007; Petrovic et al. 2002).
Other scientists argue that placebo responses are better understood using a model
of classical conditioning or ‘‘stimulation substitution,’’ emphasizing a primarily
automatic unconscious process capable of eliciting health beneﬁts. Classical
conditioning posits that a previously experienced response to active medication
(unconditioned response) plus the administration of a pill (conditioned stimulus)
causes a subsequent positive response from the provision of a dummy pill alone
(conditioned response) in a manner exempliﬁed by Pavlov’s dogs (Turkkan 1989;
Ader 1997). Well-designed laboratory experiments on both animals and humans had
demonstrated that classical conditioning inﬂuences immunological, endocrinal,
intestinal and other bodily functions (Pacheoco-Lopez et al. 2006).
Some have argued that the expectancy and conditioned response models are not
mutually exclusive, that both involve learned behaviors, that conditioning can lead
to conscious expectations and that expectation can lead to stimulus substitution
responses (Steward-Williams and Podd 2004; Klinger et al. 2007). Nonetheless,
several experiments have demonstrated that expectation and conditioning are
distinct, and can operate through unique biochemical mechanisms, and that these
pathways can be combined to produce greater pain relief than either component
alone (e.g., Amanzio and Benedetti 1999; Colloca et al. 2008).
Though receiving less attention in recent years, anxiety reduction has also been
implicated as contributing to placebo responses (McGlashan et al. 1969; Shapiro
et al. 1973; Evans 1974; Price et al. 1999; Staats et al. 2001; Price and Soerensen
2002; Geers et al. 2005; Vase et al. 2005). The essential idea is that reduced anxiety
encourages the experience and interpretation of ambiguous sensations to be
perceived as less threatening, dangerous and disruptive. Anxiety, to use ‘‘signal
detection theory’’ language, lowers the participant’s ‘‘response criterion’’ so that
fewer sensations are experienced or registered as noxious (Allan and Siegel 2002).
What would have originally been a menacing or discomforting signal and a
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unimportant or just not worthy of much attention (Lundh 1987; Geers et al. 2006).
Very recently a ﬂurry of studies have found neurochemical (e.g., cholecystokinin)
and neuroanatomical (e.g., left hippocampus signal increases) correlates of nocebo
treatments (i.e., placebo treatments administered in a context of anticipatory
anxiety) (Benedetti et al. 2006; Kong et al. 2008; cf. Petrovic et al. 2005).
Biomedicine has also proposed several other contributing factors to the placebo
response in RCTs. Report bias (the tendency of subjects to report what they think
the researcher wants them to report; what psychologists call ‘‘demand character-
istics’’) is sometimes considered an important dimension of the placebo response
(Crowne and Marlowe 1960; Orne 1962; Knight et al. 1986; Cleophas 1995).
Another factor may be distortion in memory. Psychophysics has pointed out that
recalled discomfort tends to be of a higher magnitude than the same discomfort
measured contemporaneously (Price et al. 1999; Rainville et al. 2004). And,
inevitably, genetic polymorphisms have been implicated (Furmark et al. 2008).
Given the various contributing factors believed to be involved and the different
possible biological pathways uncovered in laboratories, theorists have begun to
abandon unitary theories of a placebo effect and discuss the placebo effect as a
spectrum of responses (Benedetti 2009; Kaptchuk 2008).
In contrast to biomedical perspectives, medical anthropologists often adopt a
constructionist view, that is, that the individual’s experience of ‘‘placebo treatment’’
and its effects involves an active synthesis of factors other than those included in the
purely cognitivist or behaviorist models, for example, personal history, evaluations,
and the organization of the ‘‘self’’ and its narrative trajectory. Fundamental to all
these approaches is a distinction between ‘‘illness’’ and ‘‘healing’’ as terms for
referring to subjective and socioculturally constructed aspects of medical experi-
ence, and ‘‘disease’’ and ‘‘cure,’’ which refer to biomedically deﬁned biological
conditions (Eisenberg 1977, 1983). Some anthropologists have suggested that the
‘‘placebo response’’ may be better conceptualized as a ‘‘culturogenic’’ factor (Hahn
and Kleinman 1983; Kleinman 1973) or as a ‘‘meaning response’’ (Moerman 2002;
Moerman and Jonas 2002). These reﬂect longer-standing anthropological hypoth-
eses that therapeutically induced changes in the ‘‘meaning’’ that patients ascribe to
their illness, self and social relations may contribute to healing (Frank 1961;L e ´vi-
Strauss 1963; Tambiah 1977; Moerman 1979; Dow 1986; Csordas 1994). The
factors that these theories identify as contributing to efﬁcacious healing include
culturally powerful metaphors and symbols (especially those that refer to or directly
contact the patient’s body), the healer’s prestige, social interactions with relatives
and community members in the course of preparations and performance of ritual
and the contributions of gesture, recitation, costume and iconography to the overall
‘‘performative efﬁcacy’’ of the ritual. Also, other factors that vary from one patient
to another include personal history, cognitive models, favored narratives of the
‘‘self’’ and cultural values.
An additional explanation for placebo effects that is shared by both biomedicine
and anthropological perspectives and is usually described as the patient–physician
or patient–healer relationship (e.g., Adler and Hammett 1973; Kleinman 1988;
Stewart 1995; Brody 1997; Di Blasi et al. 2001). The clinical encounter embeds a
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(e.g., diagnosis, conﬁdence, explanatory models, treatment plans, sanctioning of
sick role), emotional factors (e.g., empathic witnessing, compassion, reassurance,
respect, active listening, collaborative trust, opportunity for catharsis), practitioner
behaviorial factors (e.g., head-nodding, bodily postures, eye gaze and thoughtful
silence), patient behaviorial factors (e.g., requesting relief, complying with healing
regime), sensory factors (e.g., touch, smells, sounds, bodily feelings), aesthetic
factors (e.g., stylized and dramatic movements and gestures, evocative weaving of
microlevel ritual details with macrolevel meta-concerns, linkage of hope with
persuasive rationale) and symbolic processes (e.g., authoritative healers, needles,
pills, diplomas, healing environments). Many of these components overlap with
other proposed mechanisms discussed earlier. In fact, most of the earlier-proposed
mechanisms clearly would need the ‘‘activation’’ of the patient–healer encounter
and could not exist independent of it.
Our team is unfamiliar with any concrete implementation of qualitative
methodologies or anthropological analyses to prospectively investigate the expe-
riences of patients who are undergoing placebo treatment in the context of an RCT.
As a preliminary step toward ﬁlling this lacuna, our team opted to embed a
qualitative study within a larger RCT to learn more about the experiences of patients
undergoing placebo treatment. In this article we report a portion of our ﬁndings
from the qualitative interview data obtained in that study. The questions informing
this part of our analysis were: What do patients experience, think and feel when
undergoing a treatment that they have been told may be a placebo? What are
patients’ expectations for improvement in a placebo-controlled clinical trial? How
do patients describe perceived improvements while under placebo treatment? And
how do patients reconstruct their illness and potential healing as they undergo the
experience of the RCT? Elsewhere, we will report on other aspects of patients’
experiences including issues of embodiment, explanatory models, narrativity and
changing interpretations of the social support available to them.
Methods: The Parent Quantitative Study
Using standard RCT procedures, the parent study was designed to quantitatively
investigate placebo effects in patients with irritable bowel syndrome (IBS)
(Kaptchuk et al. 2008). The study took place between December 2004 and April
2006. We selected IBS as a model illness for this study because previous RCTs had
shown a large positive response in placebo groups (Patel et al. 2005). Biomedicine
deﬁnes IBS as a functional gastrointestinal disorder characterized by chronic or
recurrent abdominal pain or discomfort, usually in the lower abdomen, which is
associated with disturbed bowel function and feelings of abdominal distention and
bloating (Longstreth et al. 2006). IBS appears to involve alterations in intestinal
motility, visceral hypersensitivity and abnormalities in the brain-gut axis that
processes visceral information. Anxiety disorders are higher in IBS patients
compared to the general population (Lydiard 2001; Botha and Libby 2006) and
psychosocial distress both exacerbates and is a consequence of IBS (Drossman et al.
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in clinical trials are based on validated scales of patient reports.
Our qualitative study was embedded in a 6-week, three-arm, single-blind RCT
(n = 262) designed to test the hypothesis that the magnitude of the placebo
response could be systematically augmented by progressively combining three
components of the response to placebo: (1) the patients’ experience of observation/
assessment, (2) the performance of a therapeutic ritual (placebo treatment) and (3)
an augmented patient–practitioner relationship—in a manner resembling a graded
escalation of ‘‘dose’’ (analogous to dose dependency). For the ﬁrst 3 weeks, patients
were randomized to either (1) no treatment waiting list, (2) biweekly ‘‘treatment’’
with placebo acupuncture within the context of a ‘‘limited’’ practitioner interaction
or (3) biweekly ‘‘treatment’’ with placebo acupuncture within the context of an
‘‘augmented’ patient–practitioner relationship. After the ﬁrst 3 weeks, half of the
patients on placebo treatment were rerandomized to continue on placebo treatment
for an additional 3 weeks and the other half were assigned to 3 weeks of genuine
acupuncture. The main outcome of the trial was in the ﬁrst 3 weeks; the additional
3 weeks of placebo treatment was considered a follow-up. (The genuine acupunc-
ture comparison was considered an independent secondary nested study and not
included in the primary RCT analysis or this report; Lembo et al. 2009.)
In the ‘‘limited’’ treatment group the acupuncturists explained that the RCT was a
‘‘scientiﬁc study’’ and they had been ‘‘instructed not to converse with patients.’’
They also administered placebo acupuncture. This was as close to a treatment
without a therapeutic interaction as possible. In the ‘‘augmented’’ treatment group,
besides the sham acupuncture, practitioners reviewed IBS symptoms and performed
a psychosocial intake in the context of warmth, active listening, empathy and
communication of conﬁdence. Placebo acupuncture was adopted because evidence
suggests that acupuncture, like many other procedures and devices, has an unusually
high placebo effect (Kaptchuk et al. 2000, 2006). We used a validated placebo
acupuncture device that is indistinguishable from acupuncture (Streitberger and
Kleinhenz 1998). The shaft of the sham acupuncture device does not actually pierce
the skin but creates the illusion of doing so by retracting into a hollow handle like a
magic sword. This device makes distinguishing the touch of a blunt needle tip from
real penetration practically impossible.
All participants were naive to acupuncture and were told both verbally and in
written informed consent that they had a 50% chance of receiving placebo or
genuine treatment. Patients were also told that the study was intended to compare
acupuncture and sham acupuncture, and were not told that the RCT’s primary goal
was to study placebo effects. They were informed about the primary goal after the
completion of the entire experiment. The ethics committee of the Beth Israel
Deaconess Medical Center and Harvard Medical School approved the RCT as well
as the embedded qualitative study. Details of the design, ethics and results of the
quantitative experiment are reported elsewhere (Kaptchuk et al. 2008; Kelley et al.
2009; Conboy et al. 2006).
The RCT produced quantitative biomedical ‘‘facts’’ about the placebo effect
(Kaptchuk et al. 2008). The outcome measures conﬁrmed our hypothesis that the
three arms behaved in a ‘‘dose–response’’ manner: waitlist\limited\augmented.
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statistically and clinically signiﬁcant and showed that placebo effects could be
manipulated in a manner analogous to dose escalation. The arm with the augmented
patient–practitioner relationship reported symptom improvement on a magnitude as
great as any medication approved for IBS by the FDA.
Qualitative Study Methods: Setting, Sampling, Interviews and Analysis
In addition to the quantitative RCT, an additional 27 patients (9 in each arm) were
randomly assigned to participate qualitative interviews at baseline, 3 and 6 weeks.
This paper reports on the qualitative subjects who were assigned to either placebo
condition (‘‘limited’’ or ‘‘augmented’’) for the ﬁrst 3 weeks and the half of those
subjects who continued for an additional 3 weeks of placebo treatment. Of the 18
qualitative subjects who were assigned to either the augmented or the limited
placebo treatment arms, 13 completed the study, although one did not cooperate
with the interview process. This report is based on interviews conducted at baseline
(12 patients), 3 weeks (12 patients) and 6 weeks (6 patients) with subjects who were
randomized to continue on placebo treatment.
The 12 qualitative subjects were aged between 23 and 65 years, with an average
of 43 years (SD = 17 years). Seven were women and ﬁve were men. Most patients
reported modest to dramatic improvement in their IBS symptoms. (Of the two who
did not, one reported improvement at 3 weeks and then returned to her normal
situation at 6 weeks.) Six patients were in the ‘‘limited’’ patient-practitioner
relationship placebo group, and six in the ‘‘augmented’’ interaction group.
Although the quantitative measures of IBS symptom severity found a signiﬁcant
difference between the augmented and the limited treatment groups, a careful
examination of the qualitative interviews found little obvious difference between the
accounts given by the two groups. With a few exceptions, which are noted below,
the same kinds of words, experiences and perceptions seem to mark the testimonies
of both groups. Our qualitative interviews themselves may have served as a
supplemental patient–practitioner relationship for subjects assigned to the limited
arm and thereby obscured what might otherwise have been signiﬁcant differences
between their accounts and those of the augmented subjects. The interviews seemed
to act as a second level of augmented clinical interaction. In fact, the qualitative
patients in the limited group had signiﬁcantly more improvement than those patients
who were only in the limited quantitative study. Despite this difference, because the
interviews from the augmented and limited were not distinguishable, the two
placebo groups are mostly not distinguished in this analysis, except in a few
instances when a differential trend seems to exist. Also, except for the few instances
noted, no characteristic of the qualitative interviews distinguished those who only
completed the 3-week placebo treatment from those who went on to complete a
6-week course of treatment.
Three semistructured agenda-guided, open-ended interviews were conducted
with each patient. The agendas, which were slightly different for the interviews at
baseline, midpoint and endpoint of the trial, consisted of questions focusing on
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and what changes were expected from the treatments—and also provided probes
designed to elicit descriptions of somatosensory experience, explanatory models,
images/metaphors and narrative accounts—in each thematic area. Interviews lasted
between 15 and 45 min and took place in rooms nearby those in which treatments
for the RCT were performed; that is, the general environment was that of a research
ward in a large teaching hospital. All sessions were audiotaped and transcribed.
A medical anthropologist (E.J.) conducted most of the interviews. However,
because of scheduling conﬂicts, three patients were interviewed by a backup
sociologist (L.C.). Patients had the same interviewer for all three sessions with one
exception, again due to schedule conﬂicts. The interviewers only saw the patients
during the interviews and were not otherwise engaged with them.
All members of our core qualitative team (T.K., E.J., J.S., L.C., C.K.)
participated in developing a priori coding categories on the basis of theoretical
interests, and these were supplemented and reworked during the early phase of
coding. In general, the ﬁnal scheme allowed for coding not only by theme, for
example, feelings/thoughts about their treatment, expectation and experience of
improvement, but also by forms of discourse, for example, explanation, narration,
imagery and metaphor. Ultimately all of the investigators developed their own
variant of the coding scheme, depending on their particular research interests. For
this paper, two investigators (T.K. and J.S.) coded the interviews and met regularly
to compare coding and resolve differences. Other investigators also gave advice and
feedback. Other team members will report their own research hypotheses and
ﬁndings elsewhere. Below we report on the main themes that emerged concerning
patients’ experiences considering the possibility they may receive placebos, their
expectations and reasons for joining the RCT and their monitoring and interpre-
tation of changes in their illness while being treated with placebo. All names are
pseudonyms.
Outcomes: Thinking about Placebo
Deliberating Treatment: ‘‘I’m Anxious…to Find Out…Whether I’m on
Placebo’’
Most theoretical analyses of placebo effects assume that it is easy for patients to
have a positive expectation of the novel therapy and to overlook or neglect the
possibility that they may be receiving placebo, even though that possibility
presumably was explained in the informed consent. Contrary to this assumption,
when asked directly, our patients consistently expressed their awareness that they
might be receiving placebo treatment, and persistently attempted to resolve their
uncertainty by heightened surveillance, investigation and interpretation of various
aspects of their experience.
After the patients had begun to receive treatments at interviews 2 and 3, our
interview team asked ‘‘Do you think you’re receiving the real acupuncture or the
placebo acupuncture?’’ Patients consistently expressed a deep interest in this
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in our interviews, all were highly engaged in questioning the ‘‘realness’’ of their
treatment and frequently referred to the intervention in words similar to Emily’s:
‘‘these treatments—whether they’re real or fake….’’ As all were naı ¨ve to
acupuncture, many had questions about what ‘‘fake’’ acupuncture might entail.
While most patients experienced the sensation of needle penetration with the
placebo device—the placebo needle provided a sensory experience that patients
always interpreted as penetration—they continued to question whether they might,
nevertheless, be receiving placebo. They often pondered and carefully analyzed the
situation. For example, Kate deliberated:
Mmm … well that’s another thing I’ve been speculating about, you know. I
don’t know if the real acupuncture is just in different spots because I know I’m
having needles put in, and I don’t know if the placebo acupuncture is just in
different spots that are, perhaps less effective. I have absolutely no idea if … it
[is] just a less-effective location, than not. I don’t know if it’s real or placebo.
Abigail had a similar issue: ‘‘All right, I’m guessing … my guess is that I’m
getting the real treatment…. But maybe it is [that in] a real treatment they’re
inserted more. I don’t know.’’ And David noted: ‘‘I’m anxious at some point to ﬁnd
out, when it’s appropriate, whether I’m on the placebo or [if I] am in the other one.
And if I’m in the placebo, I’ll be disappointed, but I will understand that it’s part of
the program.’’ Francis proposed another theory of placebo treatment this way:
I don’t even know if the placebo is one [where the acupuncture] … just hits
relaxation things or anything, but that was one of my theories … that maybe
the placebo isn’t speciﬁcally for IBS symptoms, but for relaxation to see if
relaxation affects how the IBS symptoms are.
Outcomes: Discourses of Anticipation and Joining the RCT
The transcripts reveal several distinct variations of discourse on patients’
anticipation for the outcome of the trial. These revolved around distinctions among
‘‘expectation,’’ ‘‘desperation’’ and ‘‘hope.’’
Expectations and Desperations: ‘‘I Haven’t Anything to Lose’’
As mentioned earlier, an important theory of placebo response is that positive
expectation activates symptom improvement. Contrary to this, ten of our patients
expressed more or less neutral expectations. For example, Kate said: ‘‘I can’t say
I’m expecting that much, but I think if something did happen, it’d be a pleasant
surprise…. It is worth a shot because otherwise, if nothing else, I’m no worse off
than I am today, you know…. I haven’t anything to lose.’’ And Abigail repeated a
bleak chorus with: ‘‘I guess it’s a long shot, I don’t know. I have no clue.’’ Fred
summarizes this sense of neutral expectations by saying: ‘‘I really have no
expectations whatsoever, you know.’’
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IBS patients, probably tempered any positive expectations. Despair lurks in these
dialogues. Barbara lamented:
You get to a point where you’re so desperate, you’ll try anything. People told
me if I wore pink everyday, I would do it. I really would try anything. If they
told me that I should drink saltwater, I would try it…. I would like it to work.
Um. If it doesn’t work, well, I tried, so I didn’t really lose.
Greta repeats similar ideas: ‘‘I mean I’m desperate. I’ll try anything. I’ll just—I’ll
try just about anything.’’ Deb continued the same sentiment: ‘‘I’d had a particularly
bad year and I wasn’t getting any response from the ﬁber, you know, and I wasn’t
taking Zelnorm or doing anything else, so I thought, ‘You know what, this can’t
hurt.’’’ And Alan passively states: ‘‘Not really. I don’t have any particular
[expectations], no. I just want to come for the experience and see what happens.’’
Only two participants expressed positive expectations, if still a bit cautiously.
Emily simply remarked, ‘‘I think it will help me reduce some of the symptoms,’’ and
Ben thought, ‘‘I think it’s gonna work better than the Celantathral [an experimental
drug that was ineffective for the patient] … and I’m gonna be okay because I’m not
gonna be one of the guys getting the placebo. And I gotta think that way, and if I
am, and if I am getting the placebo and, you know, and who knows?’’
Hope: ‘‘I Mean, I Don’t Expect Anything. I Hope that it Will Help’’
If positive ‘‘expectations’’ were in short supply for our participants, something
labeled ‘‘hope’’ was spontaneously raised as a contrast to positive expectation by 7
of our 12 patients. Many patients seemed to distinguish between what they could
‘‘expect’’ (likelihood of improvement or failure) and what they could ‘‘hope’’
(desire for improvement) or not ‘‘hope’’ for (continued therapeutic failure).
When the interviewer asked Deb, ‘‘And what do you expect to get from the
acupuncture treatments?’’ her response was, ‘‘I don’t expect anything. I hope that it
will help me.’’ Abigail reﬂected in a similar fashion: ‘‘Hey, you know if, maybe
there’s some treatment that can help me. But I have no idea. I’m just hopeful.’’
Francis echoed: ‘‘I’m hoping the acupuncture will work.’’
Even after experiencing considerable improvement after 3 weeks of treatment,
when asked, ‘‘Do you have an expectation of what will happen from this point?’’
Deb seems to protect herself from disappointment: ‘‘That’s what I’m curious about.
Because now I’m feeling so good, and I’m at this nice point. I don’t know now if my
body [has] made a sufﬁcient adjustment. I’m hoping that I’ve kind of made a
change.’’
Outcomes: Accounts of Change
In each interview, participants were asked to describe any changes they ascribed to
their involvement with the trial. With the exception of one person, all had
meticulously and carefully scrutinized their symptoms, their behavior and their lives
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worlds. Although our sample was small, we identiﬁed several rhetorics and idioms
of change. Some patients described an uneven course of improvement, while others
reported a steady progression. Even if patients experienced great improvement, their
descriptions might have a dimension of doubt. Some devised ‘‘tests’’ to ascertain
improvement, and some pondered whether any suspected improvement might be
just the natural course of their illness or only their imagination. Some patients
noticed dramatic improvement in their social relationships, negative emotions and
behaviors or symptoms unrelated to IBS as biomedically deﬁned.
Outcomes: Idioms of Doubt
The patients’ knowledge that they might be receiving placebo treatment cast doubt
on perceived improvements, and this was expressed in a number of different ways
that turned on their past experience of the ﬂuctuation of symptoms, the idea that
those perceptions may have been due only to a change in their thinking and qualiﬁed
any statement about possible improvement with markers of equivocation.
‘‘You Know it Fluctuates Anyways’’
Like the researchers themselves, the patients were concerned with distinguishing
improvements that could have just been normal waxing and waning of their IBS
from changes that were attributable to their treatments. Questions of causality were
invoked to cast uncertainty and hesitancy over the attribution of perceived
changes—even when they were dramatic. The vagaries of spontaneous amelioration
created a moving benchmark that made unambiguous claims of improvement
problematic.
Although Abigail experienced signiﬁcant improvement, she still was concerned
with attributing causality:
It’s [IBS] been somewhat mitigated. I don’t feel as bloated. I don’t feel as
constipated. I’m able to go to the bathroom a little bit easier…. And the IBS
seems to have improved but who knows if it has anything to do with this
acupuncture? It could be, you know, it ﬂuctuates anyway.
Francis had similar concerns:
I have not been as constipated…. I wanted to go to the bathroom and I said,
‘‘Hmm, I wonder if this is just a coincidence or what.’’
Ben, who originally complained of difﬁculty going out in public because
bathrooms might not be nearby, later reported considerable improvement and stated
that
I get out more, you know. But it’s like that has a lot to do with the change in
the weather, too. If the sun’s out there, I can’t stay in.
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We have already described how patients were pervasively concerned that they might
be receiving placebo treatment. Like the possibility of typical normal ﬂuctuations in
IBS symptoms, the knowledge that they might be receiving placebo treatment was
cited to cast a cloud over the veracity of perceived improvement. At 3 weeks,
Abigail ruminated:
Hmm. I think it’s gotten progressively [better] a little but, again, I don’t know
… it’s hard to tell. Then I keep thinking, ‘‘Well maybe the treatment’s aren’t
even real,’’ so how do I know if it has anything to do with that?
Even with dramatic improvement at 6 weeks, Abigail continued to consider the
possibility of a less than ‘‘genuine’’ recovery:
It makes you feel pretty stupid, I mean, because you think, ‘‘Oh, I seem to be
getting better.’’ Or, ‘‘Maybe I’m making the whole thing up.’’ You know. I
don’t know…. You know, I just … I feel much better, but who knows if it has
anything whatever to do … unless it’s like a placebo effect like they say.
Deb expressed a similar predicament:
I mean, like, my gut-level feels like I’m in the right group, because there’s
been such a marked change, but again it could be [that], psychologically, I was
just ready for this to happen … you know, I could have made it happen on my
own.
To avoid the potential of cognitive dissonance inherent in this situation, at the
end of the trial, Alan preferred not to know whether or not he had been on placebo:
‘‘Well, it worked. You know. It worked. I mean … if I wasn’t [receiving genuine
acupuncture], I don’t know if I’d want to know.’’
‘‘I’ve Been Kind of Wondering’’
While both the ‘‘augmented’’ and the ‘‘limited’’ treatment arms expressed doubt
in terms of natural ﬂuctuations and the possibility of placebo treatment, an extra
dimension of doubt seemed evident in the discourse of those patients who
received a limited patient–practitioner interaction. Despite their measurable
scores of improvement on the quantitative measures, especially at 3 weeks, there
was a more hesitant communication. Perhaps this reﬂected the lack of a
reinforcing patient–practitioner relationship that may have aided the consolida-
tion of perceptions of change in the augmented arm. Often patients in the limited
group prefaced or qualiﬁed their reports of change with expressions of
uncertainty such as ‘‘I don’t know’’ or ‘‘I think.’’ Often patients, like Kate,
seemed unsure: ‘‘I’ve been kind of wondering [about any changes].’’ Many of
the responses in the limited arm had a ‘‘yes and no’’ quality, a back-and-forth
style of hedging, as is noticeable in the three women quoted below, all
describing their improvement at 3 weeks.
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It’s kind of like a very slow melting. Kind of like dry ice. I mean you see it but
it’s enough that you notice the difference. I mean it’s not so insigniﬁcant that
… you know, you barely notice it. I mean you deﬁnitely notice it and you do
see results. But not one hundred percent.
Relief is perceptible but sometimes remains subtle, as Francis explains:
I have not been as constipated. I have actually been going to the bathroom and
I don’t know if it’s just a change in food, but I don’t think so. Really, I don’t
change … to a drastic degree.
Kate continued:
It’s no cure. It deﬁnitely has not cured me of anything, but I think on a day-to-
day basis, I’d say maybe there’s an improvement in just general discomfort.
Such tentativeness is not altogether missing in the augmented group. For
example, at 3 weeks, Emily says: ‘‘I’m not sure if that could be, but, uh, yeah the
symptoms are, I mean … currently, I feel a bit better than I felt…. It’s hard to tell.’’
At 6 weeks she became more emphatic.
Outcomes: Idioms of Certainty
Despite the shadow of limited expectations and worries about placebo treatment,
many of our patients—in both placebo conditions—expressed a certainty in their
perceptions of improvement. This deﬁnitiveness often turned on notions of
‘‘progression’’ or gradualism, or on references to self-described ‘‘tests’’ or
experiments they had devised.
‘‘It’s Been a Nice Progression’’
Deb, who was in the ‘‘limited’’ arm, reported steady improvement at 3 weeks and
complete relief at the end of 6 weeks. At 3 weeks she said:
Like before I felt everything was just tight in there and compressed and um,
now I just feel like it’s kind of eased it a little bit…. It’s been gradual, but
consistent…. I started noticing that my stomach was kind of going down, and
my stools kind of started changing. It’s been a nice progression.
At 6 weeks she said, more deﬁnitely:
It’s just great. I mean, I just continue to improve. I mean, I feel like I’m 99%
better and … I mean, everything [has improved]. All my original symptoms. I
don’t feel, um, all the bloating and the constipation. And just, you know, like I
say most times stools have totally changed.
Similarly, Ben, who also had dramatic improvement in the ‘‘augmented’’
condition, provided another example:
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diarrhea and you’re not … you say: ‘‘Wow, that’s nice.’’
When improvement was steady it was invariably gradual. As Ben again
observed:
It doesn’t come on strong like, like an Imodium [a common antidiarrheal over-
the-counter medicine]. [Imodium] kind of like affects you like in a rough
way…. It [the RCT intervention] just kind of like smoothes in there and it just
stops [the diarrhea]. And then some point along the way, you realize, you
know, you don’t have diarrhea.
Abigail, in the limited condition, also experienced steady incremental improve-
ment: ‘‘I seemed to notice a change pretty soon. But I think it gradually got better
even though I did notice something after one or two treatments.’’
Unlike the other patients, Alan, in the ‘‘augmented’’ arm, reported that his
improvement meant he was less focused on his symptoms: ‘‘I think [the symptoms]
had a steady improvement. I started noticing that throughout this process that I
stopped thinking as much about my problems, because they weren’t there as much.’’
‘‘I Want to See if this Works, You Know’’
For some patients, certainty as to whether they had beneﬁted from treatment
required actively testing or challenging their condition. They sometimes spoke as
lay scientists for whom the outcomes of their tests constituted a particularly
convincing idiom of certainty. Self-experimentation was meant to rescue certainty
from doubt. For some patients this may have related to a high level of education.
While patients in the study were allowed to continue on any medication regime that
they had previously taken for at least a month prior to starting the trial, Ben spoke of
discontinuing all his medications to test whether the treatment worked.
I know the doctor here told me, he says, ‘‘You can take whatever you have to
take, you know, while you’re on this [treatment protocol]. We don’t care. You
can take a medication while you’re on this.’’ But I can’t see me wanting to
take a medication if I’m on this. I want to see if this works, you know. I don’t
want to do anything else [while I’m in the study].
Kate also experimented:
I kind of put the acupuncture to the test, maybe two weeks ago or something
and had a big meal with a lot of things that I probably shouldn’t eat.
David also performed his own test:
I was prescribed an anti-spasmodic…. So two weeks before I started this
acupuncture, I stopped. I made an executive decision. I said I’m not going to
do this because I don’t want to mask the acupuncture.
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Patients most often described changes in the salient symptoms of IBS: pain,
discomfort, bloating, diarrhea and constipation. Certainly in the quantitative RCT,
patients were asked to rate these symptoms many times and in many different ways.
In this qualitative study, subjects often also described speciﬁc changes in other areas
as being especially important, including freedom from formerly necessary dietary
restrictions, improvement in social relations, reduction in emotional distress and
increase in positive affective states.
‘‘I’m Not Afraid to Eat’’
Diet and personal hygiene were important. Subjects spoke about becoming socially
more ‘‘normal’’ and of the relief they felt as behaviors once routinely needed to
maintain control over the body and to manage potentially stigmatizing ﬂatulence or
diarrhea fell away (cf. Goffman 1963).
Ben described his improvement this way: I’m not afraid to eat things, you know,
like corn and stuff. I’m not afraid to eat. Like before I’d look at something and
think, like, ‘Hey, it might make me go [to the bathroom].’ While Alan said, ‘‘I ﬁnd
myself eating foods that I haven’t eaten in awhile or, you know, drinking caffeine if
I want it because I don’t have such severe attacks anymore.’’ And, Kate: ‘‘I’ve eaten
some foods that I would have thought would have triggered me off more [precipitate
an IBS attack], some of the vegetables and chick peas and things like that usually
give me a lot of trouble didn’t seem quite so bad.’’
Abigail also noticed dietary changes:
Like usually I have to take Citrucel and I have to have a salad, a certain kind
of salad, at night … in order to go to the bathroom in the morning. Well I
haven’t been having the salad and I haven’t been having the Citrucel and I’ve
still been able to go to the bathroom.
David reported personal hygiene and telephone calls to be his yardstick for
measuring change:
The urgency in the beginning was such that I would have minimal warning.
Now it’s much more controlled. Now [I] have the luxury of saying, you know,
I am going to go the bathroom [after lunch] but I’m going to make one more
phone call…. Before [the study] it was men’s room ﬁrst, [the] phone call was
deﬁnitely later.
‘‘I’ve Taken Steps to Leave My Husband’’
Our participants sometimes perceived their treatments precipitating positive
changes in social relationships (including shifts in marital relationships), new
emotional stability or other improvements not usually thought of as aspects of
improvement in IBS. This occurred more often and more dramatically in the
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in the ‘‘limited’’ group, with reports of increased ‘‘emotional calmness.’’
For example, Greta had this to say about her marriage:
Well actually my husband and I are in the process of separating…. We [have]
moved into different rooms in the same house. For me it’s important to do that.
The treatments … reinforce me, [they] give me some energy to take the steps
to [leave my husband].
Ben’s change in marital relationship went in a different but still positive
direction:
I’m calmer than I used to be. I know I don’t yell as [much as I used to]. I was
talking to my wife yesterday and I said, ‘‘I don’t know. Maybe it is this.
Maybe it is the acupuncture.’’ I used to raise my voice and I used to yell a lot,
when I talked to people … and I ﬁnd myself not doing that. And if [I] am
doing it, I catch myself.
David felt renewed emotional stability and new moderation with alcohol:
And I feel that acupuncture, if nothing else … has brought somewhat of a
tranquility to my life. It’s a very interesting, it’s a very subtle change of how I
feel about myself, and I’ve enjoyed it. There are times when I’m much
generally more calm[er]. However, there are times when someone will do
something that will aggravate me, and I’m not afraid to speak up to them and
say how I feel…. [And] I cut down on my drinking, so I’m not waking up in
the morning during the night. And so I’m sleeping better because the alcohol
[drinking] has diminished.
‘‘[I] Feel Much More Optimistic About Life’’
Emotional improvement was often mentioned in the interviews. Abigail stated, ‘‘I’m
sort of … feeling more compassion for myself…. Well, it [the treatment] just makes
me feel much more optimistic about life you know. You know, it makes me want to
do stuff. Who wants to do stuff when they feel real crummy?’’ Sam, who otherwise
had no improvement in irritable bowel complaints reported: ‘‘I think I’m less
fearful, I get less anxious over things that are happening.’’
Importantly, all patients mentioned at some time during the interviews that,
immediately after treatment, they, like Alan, felt ‘‘deﬁnitely calmer.’’ Interestingly,
many patients also reported that this feeling continued into their routine lives.
Francis, who was in the limited group, reports: ‘‘It was just relaxing. I just found it
very relaxing. Maybe that’s because I don’t usually lay down in the middle of the
day. [Laughs.]’’
Finally, other unexpected improvements occurred. As Ben reports: ‘‘I mean, you
know. Like I … I suffer from depression and … I think this [treatment] might be
helping with that … [and] you might laugh. I feel I have a stronger sex drive.’’
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Some participants cast themselves as part of the research team. Kate, also in the
limited arm, which discouraged talking, reported, ‘‘[I’m trying to stay as]
uninformed as possible and not ask too many questions, I don’t want to skew the
data or something,’’ while Ben, in the augmented interaction arm, worried, ‘‘The
only thing that bothered me was I said, you know, ‘What if I’m telling these poor
people that I’m feeling better,’ which I am, ‘and they’re giving me placebo. Doesn’t
this throw the whole thing off?’ Doesn’t it? You know! I think I was more worried
about that than anything else!’’ David describes his absolute dedication to the trial:
[The acupuncturist] said to me, ‘‘Now, if you can’t make a treatment, you
know, you call us … and we’ll reschedule them.’’ I thought, I mean, I would
crawl to get there…. I can’t imagine somebody being in a program and
missing [an appointment].
Several of our patients explicitly worried about how the acupuncturist would feel
if the trial did not succeed in proving that acupuncture worked. Some were
particularly concerned that their accounts not harm the acupuncturists.
For example, Abigail pondered:
And recently the idea has popped into my head that, ‘‘Oh my G-d, what if they
ﬁnd out that it’s not effective?’’… That’s, that is kind of scary. And then I felt
bad for the acupuncturist, too. It would invalidate what she’s doing. It must be
hard for her. If I were her, I would be peeing in my pants. Oh my G-d. [Both
she and interviewer laugh.]
Undoubtedly, this dedication to the trial and the concern for the practitioners also
represent the importance of the close, dyadic bonding that occurred during the trial.
In fact, all patients expressed conﬁdence in, trust of and appreciation for their
therapist, regardless of whether they were in the augmented or the limited arm.
Discussion
While our quantitative RCT recorded unambiguous aggregate ‘‘placebo effects’’ in
IBS, in the embedded qualitative study, we found a response to placebo treatment
that was more deliberative and complex. Perhaps such ﬁndings are inevitable when
one examines the ﬁne grain of actual experience. Improvement could mean a
reduction in bodily dysphoria, changes in bowel movements, being able to eat foods
that previously would have triggered severe symptoms, new emotional stability, or
being able to go out in public more easily. For some patients, improvement was
progressive and certain and included perceived dramatic psychosocial transforma-
tion. Others, primarily in the ‘‘limited’’ group, improvement seemed to be groping
for what Csordas (2002) has called: ‘‘incremental and inconclusive effects that
deﬁne the lowest threshold of efﬁcacy.’’ In both placebo treatment arms—
‘‘augmented’’ and ‘‘limited’’—even when patients felt completely relieved from
their symptoms, there was rhetoric of hesitation and doubt. Some patients wondered
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placebo effects. Some patients performed mini-experiments to test whether they
were really better.
Our placebo treatment clearly was not some stand-alone, miraculous event, a
deus ex machina, that dominated our patients’ perceptions. For most, treatment was
a new and uncertain perturbation of an already complex life-world. The treatments
provided the patients with an opportunity to reorganize that world, and their
improvements mirrored the multilevel, pervasive role of IBS in their daily lives.
Ambiguity often prevailed; certainty of improvement could be difﬁcult to sustain.
Our patients struggled with such questions as: Was it the therapy or the salad that
produced the improvement? Was it real therapy or dummy treatment? and Was my
digestion better or worse a week ago? Separating the placebo input from other
aspects of daily life was not easy. Their testimonies has what Bruner (1986) called
the ‘‘indeterminacy of reality’’ and ‘‘the trafﬁcking in human possibilities rather
than in settled certainties.’’
The placebo response of each patient was an idiosyncratic, variable and unstable
construction, undertaken in the novel context of an RCT composed of specialized
and authoritative procedures (i.e., informed consent, the knowledge of randomiza-
tion, the delivery of the treatment under conditions of ‘‘blinding,’’ interrogation by
social scientists). From the patient’s viewpoint, the treatment they received was
inherently ambiguous with regard to its potential to heal. From the researcher’s
point of view, that uncertainty was the raison d’e ˆtre for the blinded clinical trial. Yet
from the patients’ side, the same carefully devised blend of doubt and concealment
was a potent obstacle to the stability of any attempt to construe the treatment’s
effect on their illness. What we have highlighted here and sought to understand,
however imperfectly, are their descriptions of those often inconclusive, self-
contradictory or vacillating attempts to cast the hints of ‘‘change’’ or ‘‘no change’’
into a convincing and stable account of how the treatments were affecting them.
This ‘‘symbolic work’’ was interminable, not because of the obdurate nature of the
patients’ illness, but, at least for the duration of the trial, by design.
Our patients did not proceed from an initially determinate level of ‘‘expectation,’’
along a regular slope of ‘‘response’’ or ‘‘nonresponse,’’ to an ‘‘end-point’’ measure.
Instead, embarking on treatment with an already complex and ambivalent attitude,
they negotiated a variety of unpredictable trajectories using tactics that included
intensiﬁed surveillance of their illnesses, psyches and social relations; ‘‘experi-
ments’’ to test if they have ‘‘really changed’’; equivocal and vacillating
formulations; discourses of ‘‘expectation’’ and ‘‘hope;’’ certainty and uncertainty,
as well as other maneuvers that we have undoubtedly failed to discern in our small
sample—all in an attempt to construct a convincing, stable account of their response
to treatments. In short, they traversed a turmoil of therapeutic uncertainty that was a
direct consequence of the deﬁning features of the RCT—placebos, informed
consent, blinding—which made the ‘‘symbolic work’’ essentially unstable, shifting
and protean (Le ´vi-Strauss 1963; Obeyesekere 1985, 1990).
Our ﬁndings challenge many of the dominant theories concerning placebo effects
in RCTs, and encourage consideration of novel emergent views. Clearly, expectancy
as conventionally understood does not provide a completely adequate account for
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desperation was more typical. Many spontaneously expressed ‘‘hope,’’ which they
explicitly distinguished from ‘‘expectation.’’ This ﬁnding corroborates two retro-
spective studies of patients who had previously participated in RCTs. Stone et al.
(2004) interviewed nine participants from ﬁve different RCTs about their initial
expectations. In this study, only one participant reported expectations of beneﬁt,
while the remaining eight distinguished clearly between hoping they would achieve
some beneﬁt and having any expectation of improvement. In another study, Di Blasi
et al. (2005) performed 46 telephone interviews with patients who had completed a
placebo-controlled pharmaceutical RCT for heel pain. While most (79%) reported
not having had ‘‘positive expectations’’ prior to receiving treatment, 52% had
‘‘hoped’’ that the treatment would help. Other qualitative researchers have noted a
similar caution in patients recruited to RCTs and, en passant, noted that individuals
join trials with an attitude, to quote the patient’s own words, of ‘‘Why not try it, just
to see what it can do and if it can help good, great, but if it can’t, we tried’’ (Conboy
et al. 2008; cf. Paterson et al. 2008).
It is possible that some patients’, denial of a ‘‘positive expectation’’ may have
been partially determined as much by their concern to appear sophisticated with
regard to this issue when being interviewed by a professional researcher as by any
introspective discrimination between their own cognitive states. It is possible that
these patients, who typically had already experienced multiple failed attempts at
therapy for their IBS, may have consciously rejected or limited any expectation of
beneﬁt in order to avoid another disappointment. It is also possible that we are
dealing with a disjunction between patients and researchers/clinicians regarding the
meaning of ‘‘hope’’ and ‘‘expectation’’ (cf. Good-DelVecchio et al. 1990).
It would seem that some notion of a positive outcome ﬁgured in our patients’
construction of ‘‘hope’’—as they had, after all, undertaken an arduous effort to
actively participate in an RCT involving a novel therapy. While they neither
evinced ‘‘expectancy’’ of a positive outcome, in the probabilistic terms of clinical
researchers, nor uncritically accepted the treatment as genuine, they may have
negotiated the question of treatment effectiveness ‘‘not in the sense that their truth
value is certiﬁed by logic or argument but in the sense that they are taken into the
imagination and lived with, if only for a time’’ (Kirmayer 1993). Hope was a kind of
passive volitional intention combined with imagination, will and acceptance. Hope
was not so much a prediction as an existential stance: a lifejacket against despair.
The emergent neuroscience hypothesis of ‘‘prospection’’ provides another way of
thinking about our ﬁndings concerning ‘‘expectation’’ and ‘‘hope.’’ ‘‘Prospection’’
proposes that people constantly build ‘‘simulations’’ of the future in their minds to
explore different future scenarios. This ‘‘multiplex theater’’ operates as a ‘‘stage’’ or
‘‘representational space whereby simulations of the future can be constructed and
explored. A proposed detail of this constructional space is that it allows a
representation of current reality and also secondary representations that explore
future possibilities’’ (Buckner 2007). From this point of view, our patients are seen
to have engaged in dynamic process that entertained multiple possibilities of the
future (and even the present). Prospection allows for such multiple possibilities,
which could include improvement, worsening and little change. Hope seems aligned
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including amelioration.
Still another, more anthropological rubric for the examination of ‘‘expectation’’
and ‘‘hope’’ is the concept of ‘‘subjunctivity’’ of illness narratives, a concept that
medical anthropology borrowed from the ﬁeld of literary criticism (Bruner 1986;
Kleinman 1988; Good 1994). In telling (or thinking) the story of their illnesses,
especially chronic illnesses, individuals are often careful to indicate some
uncertainty, if not frank hope, as to the anticipated future course. Theorists of
ritual have noted that this subjunctive ‘‘as if’’ framework can actually pull someone
into a deeper level of participation and somehow ‘‘make the illusion the reality’’
(Seligman et al. 2008). Closely related to this is the concept of ‘‘therapeutic
narrative,’’ which recognizes that the very process of clinical treatment inevitably
involves the development, whether rudimentary or elaborate, of a projected
narrative of how the patient will heal and that the patient’s participation in treatment
requires that the patient commits to some such projected story of ‘‘cure’’ or
‘‘recovery’’ or ‘‘rehabilitation,’’ even if couched in the most tentative terms, that is,
‘‘hope’’ (Mattingly 1998). (Our team will report a more detailed analysis of the
narrative features of these interviews elsewhere.)
Several of our patients attributed profound psychosocial transformations to their
treatment, including improved marital relationships and emotional stability. Given
the well-established importance of social stress in IBS (Drossman et al. 1999) and
the recognition that psychosocial suffering is an important ‘‘idiom of distress’’
(Nichter 1981), placebo-induced improvement in this domain probably should not
have been totally unexpected. It may be that improvement of IBS symptoms leads to
more comfortable performance of expected social roles and reduces social
impairment. An alternative explanation is suggested by reports of anthropologists
who have found that users of alternative therapies see their healing as ‘‘embedded
within and inseparable from a network of emotions and connectivity with others’’
(Barry 2006), and often report ‘‘whole-person effects that were characterized by
changes in strength, and changes in personal and social identity’’ (Paterson and
Britten 2003). Indeed, commentators have noted that alternative medicine’s
unusually broad self-deﬁned scope of practice (e.g., ‘‘body, mind, and spirit’’ or
‘‘holistic’’) charts a similarly broad, even indeterminate, range of therapeutic targets
(Kaptchuk 2002).
In view of the complexity of our patients’ experiences, classical conditioning,
like the expectancy model, also seems too simple in its formulation of the variables
it takes into account as ‘‘paired stimulus’’ and ‘‘conditioned response.’’ Our patients’
accounts were often self-reﬂective and seemed to include a complex interplay of
environmental clues and learning processes that included thought and imagery, as
well as preconscious perceptual processes. For example, the perceived dramatic
marital changes are difﬁcult to account for in terms of conditioning. And, as with
expectation, it is implausible that our patients’ dismal history of failed medical
treatment would have conditioned them to respond positively to the trial’s placebo
treatments, which were delivered in yet another recognizably medical environment.
Also, on this score, all patients were naı ¨ve to acupuncture.
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ﬁndings suggests that recent phenomenological efforts to ﬁnd a middle ground
between the two poles of ‘‘reﬂective consciously accessible thought’’ and ‘‘reﬂex
stimulus substitution’’ may be worth exploring for additional insights on placebo
effects. Most notably, Frenkel (2008) has suggested that placebo treatment is less
about cognitive representation of activity or reﬂection than it is ‘‘bodily engagement
in the activity itself.’’ The placebo is something experienced; it is as much
something that happens as something that one thinks and believes. From this point
of view, the individual’s experience of response to a placebo is not only ‘‘cognitive’’
in the conventional academic sense, but also, and importantly, turns on a perceptual
organization of bodily experience that occurs both prior to conscious thought and,
also, as part of conscious thought. The invocations of hope we found in our
interview data might be interpreted as an openness to experiencing what situations
offer or, to use Gibbon’s (1986) term, ‘‘afford.’’ As Thompson et al. (2009) have
recently suggested, the placebogenic environmental cues and learning processes are
not necessary ‘‘solely, nor predominately, conscious’’ and involve ‘‘direct sensory,
[affective] and embodied experience (or implicit perception).’’ For our patients, the
experience of receiving a new therapy, even if tinged with doubt, provided a
concrete opportunity for the reconstruction of ‘‘self’’ and ‘‘illness’’ in a novel
context of ‘‘healing.’’ To the extent that conscious mind is involved, it works
according to Good’s (1994) analysis, whereby: ‘‘Rather than [static] belief [or
expectation] the focus is … on interpretative activities … [which allow events to be]
confronted, [attended to,] experienced, elaborated [and conﬁrmed].’’ Our patients
attempted to construct a narrative from a series of events. Both ‘‘the immediate felt
individual subjective’’ experience and the ‘‘conscious reﬂective grasping of this
experience’’ were involved (Kapferer 1991).
Anxiety reduction could also be considered a salient aspect of the responses of
our patients. Dramatically, without any prompting from the interviewer, all our
participants said that their treatments made them feel ‘‘calmer’’ or ‘‘more relaxed.’’
Patients told us that they ‘‘got less anxious over the things that were happening.’’ It
is possible that the sometimes-ambiguous signals of IBS are experienced and
interpreted as less threatening, less alarming or more ordinary and uneventful
because of less anxiety. The placebo altered participants’ response criterion for what
was pain, disruptive or worthy of attention (Allan and Siegel 2002). Also, with one
exception, all patients claimed to scrutinize their symptoms more closely during the
trial than before the trial. This is possibly due to the social support inherent in
participating in a RCT that this self-examination took place with more detached
interest, more curiosity, less dread and less anxiety than usual, which in turn may
have led to generally lower levels of distress.
Other potential inﬂuences on our patients’ accounts are worth considering.
Report bias could have been a factor in some of the narratives of improvement.
Obviously, we did not ask patients if their responses were intended to please the
researchers. However, some patients expressed concern about how the outcome of
the trial would affect the experimenters, and it is seems possible that report bias
could have inﬂuenced their reports.
402 Cult Med Psychiatry (2009) 33:382–411
123Many of our patients’ assessments turned critically on references to memory. In
examining their interviews, we were struck, as other researchers have noted (e.g.,
Price et al. 1999), by how fragile this aspect of their interpretive process could be.
While we cannot conclude that inaccuracy of memory helped to conﬁgure the
placebo response of our patients, our study demonstrates a major role of
retrospection in their accounts of symptom change, and raises questions as to the
extent to which distortions of memory contribute to the subjective construction of
treatment outcomes. Related to memory bias, and easily as important, attribution
bias should also be mentioned as a potential contributor to magnitude of
experienced positive outcomes. IBS ﬂuctuates and, indeed, our patients often had
difﬁcult deciding whether their improvement was due to treatment or the natural
course of their illness. Clearly conﬂating such unrelated changes with treatment
outcomes could easily contribute to a more positive experience of treatment.
(However, it should be noted, attribution bias cannot explain all of the positive
changes because, as a group, patients treated with placebo did much better than
those in the no treatment wait list controls in the parent RCT.)
Perhaps most importantly, all the potential mechanisms of placebo response we
have already examined are unimaginable without the context of a patient–healer
relationship (even if sometimes it was a ‘‘limited’’ one). Separating the cognitive,
affective, physical and symbolic dimensions of this relationship from the earlier-
discussed mechanism seems impossible. All other factors seem to be intertwined
and held together by the clinical encounter. Undoubtedly, the patient–healer
interaction was a central aspect of this study (as it was in our earlier RCT), and was
necessary to ‘‘trigger’’ the transformations our patient’s experienced. Also, as
mentioned earlier, in the parent RCT of this study, when the patient–practitioner
relationship was systematically ‘‘augmented,’’ our patients registered dramatically
increased placebo responses. Its relevance to the placebo effect cannot be
underestimated.
And ﬁnally, it is worth noting that the patient interaction in this RCT had more
than the ordinary ‘‘activation’’ of a biomedical encounter. Solicitations for
participants were widespread in the print, Internet and television media. Yet,
enrolling was a challenge: patients were screened multiple times to insure they
qualiﬁed. Many procedures such a randomization, blinding and informed consent
were not routine. The RCT was both more intimate and more public. At three time
points, 452 written questions that comprised the multiple batteries of questionnaires
were administered. Nurses took vital signs and drew blood after each visit. And
patients were aware that, in a de-identiﬁed form, every detail could eventually be
published. The circumstances were extra-ordinary. And within the RCT, a second
ritual of fake acupuncture added a further layer of ‘‘extra-ordinary.’’
To summarize our ﬁndings: Patients were realistic. They were aware that they
might receive either placebo or genuine treatment. Their previous experiences with
medical treatment were not positive and many had reached the point of despair.
Motivated by ‘‘hope’’ and an openness to change, patients enacted their prescribed
roles, in what Rappaport (1999), in his study of ritual, calls ‘‘more or less invariant
sequences of formal acts and utterances not entirely encoded by the performer.’’ In
the charged atmosphere of the RCT that included intense questioning by research
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123scientists and the possibility of novel treatment, most patient engaged in heightened
self-scrutiny and reappraised their condition. The trial was accompanied by a
constantly shifting assortment of embodied sensations including bodily feelings,
symptoms, moods, laying on of hands, placebo needles, and blood tests and
embodied behaviors including the abilities to make telephone calls and consume
different foods. For almost all of our patients, through a process of self-surveillance,
the placebo treatments were interpreted as engendering positive change, sometimes
dramatically so. Yet, the cause of perceived amelioration was not necessarily
obvious and was open to multiple attributions: new treatment, normal ﬂuctuations in
bodily sensations, shifts in behaviors or even placebo effects. Narratives were often
provisional and included multiple and even contending perspectives. Ambiguity
pervaded. No single theory of placebo response seems to explain the data. In this
RCT, all proposed mechanisms could be see as embedded in the patient–healer
relationship. For most patients, what began as an ‘‘as if’’ subjunctive interpretation
of experience later became the premise for a construction of a healing encounter
built on enactment, embodiment and interpretation—ultimately experienced as
healing (cf. Rappaport 1999).
Limitations
Any inference from the results of our study about placebo treatment must be
tempered by several limitations. First, our number of subjects was small, and this
was only partially compensated for by the fact that the sample was randomly
selected. The context of an acupuncture regime might not generalize to patients who
undergo more familiar, conventional medication pill therapy (Kaptchuk and
Eisenberg 1998). Besides having potentially expansive psychological dimensions
(Barnes 1998), placebo acupuncture involves highly focused directed attention that
is enveloped by unique kinds of apprehension, anxiety and trust (Liu 2008) and
autonomic arousal (Park et al. 2008), more akin to what happens in a multisensory
healing ritual than the more medical behavior of simply taking a pill (Kaptchuk
et al. 2000) Furthermore, IBS is a complex disease and it is unclear whether the
experiences of IBS patients generalize to other conditions. That said, it seems likely
that the experiences reported in our research may apply to other conditions that are
also deﬁned in terms of patient reports of symptoms (e.g., chronic pain, depression
or chronic fatigue syndrome).
An additional limitation is that our study relied on interviews conducted at a
tertiary hospital research center and in the context of the social relationships
engendered by an RCT. Patients almost certainly viewed their interviewers as
knowing more about what they were undergoing than they did themselves, and
could easily have pragmatically adjusted their statements to this context. That said,
we do not know of any less biased, feasible method to obtain this type of data.
Finally, our study provides no data as to whether and to what extent our patients’
responses to placebo treatment may be related to any of the biochemical,
neuroendocrine or neuroanatomical correlates of the placebo effect that have been
found in recent laboratory experiments. Also, given the absence of objective
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123measures of outcome, placebo responses in this study could be mainly related to
shifts in illness experiences due to selective attention to diffuse experiences. Our
team anticipates further analyses of already gathered data to investigate such issues.
Afterthought
Some remarks on the RCT and ritual seem to be in order. The RCT claims to
identify a mathematically precise demarcation between physiological causality and
the effects of ritual. Clinical scientists developed it as a ‘‘rational,’’ ‘‘skeptical’’ and
objective apparatus to remove from medical knowledge the prejudicial taint of
human ‘‘belief,’’ ‘‘suggestion’’ and everyday subjectivity (Good 1994). Nonetheless,
and perhaps inevitably, as has already been frequently observed, from an
anthropological point of view, the RCT is a form of secular divination with its
own rituals (Blumhagen 1979; Felker 1983; Kaptchuk and Kerr 2004; Kaptchuk
et al. 2009). Importantly, the procedures of our particular RCT—conducted in the
context of a large teaching hospital, with its placebo needles, white coats and
community of practitioners and researchers, created its own version, of a ritual
‘‘cacophony of … sight, touch and kinesthesia’’ (Desjarlais 1996), and of intense
community involvement (Janzen 1976), that anthropologists have found to be
characteristic of healing rituals ‘‘in the ﬁeld.’’ And yet, the placebo ritual is more
than a biomedical-reduced version of the healing rituals found across cultures. It has
a unique characteristic: the ritual of placebo treatment in an RCT embodies a deep
suspiciousness of the ritual itself. Perhaps from the deliberate uncertainty inscribed
in the informed consent, our patients shared and embodied the RCT’s skepticism,
doubt and tacit invitation for critical self-examination. It is understandable that they
were concerned that their treatments might well lack real content and represent only
the husk of appearance (Weber 1930; Seligman et al. 2008). The placebo ritual was
presented within the context of the ofﬁcial, rational skepticism of biomedical
research. It is even possible that the RCT’s overwhelming serious skepticism
infused the ritual with the culturally charged symbolic ‘‘power’’ of biomedicine. Yet
despite the systematic infusion of doubt, or maybe precisely because of it, patients
were still affected by the placebo treatment, and testiﬁed to the salubrious beneﬁts
of this most peculiar medical ritual.
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